When bad news hits a family, everyone bonds together to be brave for each other. Thatās what happened in June 2011 when Stephanie Hansen of Austin, Texas, found out her mother had breast cancer. āI wanted to make something that my mom, dad, sister and I could all wear in ...
January 27, 2014
Henry McCance, co-founder and co-chairman of Cure Alzheimer’s Fund, talks about his commitment to ending Alzheimer’s and the venture capitalist’s approach to philanthropy.
July 15, 2016
This is your go-to spot to stay up to date on cutting edge Alzheimerās research. The goal of Cure Alzheimer’s Fund is to cure the disease and ultimately prevent it from happening at all. So far, weāve contributed 8.2 million dollars toward research and one example of our progress is that ...
August 27, 2009
Alzheimerās disease (AD) is the leading cause of dementia worldwide; we still have no cure. Plaques of amyloid proteins and neurofibrillary tangles of tau proteins are the two hallmarks of AD. The last decades of research have mainly focused on amyloid, with limited success in clinical trials to date. It ...
June 23, 2022
Sarah Treat Parshley (Sally) died peacefully on September 5, 2020 at age 65 after a prolonged illness.Ā She was the youngest of five children born to Paul C and Mary H Parshley and was raised in Glastonbury, Connecticut where she attended public schools and graduated from Glastonbury High School in ...
September 21, 2020
Dearest Family and Friends, It is with heavy, but relieved, hearts that we tell you our beloved Ron, age 78, transitioned peacefully and joyfully from our home into Godās arms on March 14, 2021, due to complications of Alzheimerās disease. How appropriate that he took his last breath on a Sunday ...
April 12, 2021
2021 There is an urgent need for a better understanding of how normal neurons in the brain are converted into Alzheimerās disease neurons, and there is an equally urgent need to identify drugs that can block or even reverse this conversion. We are developing and optimizing new human neuron testing systems ...
December 21, 2020
Vascular problems are present in almost all patients with Alzheimerās disease (AD). However, the underlying mechanisms remain unclear. Importantly, none of the currently used animal models for testing AD therapies include vascular factors. Our project will, for the first time (a) map for the āvasculomeā in AD mouse models; (b) ...
December 17, 2018
On July 6, 2023, the U.S. Food and Drug Administration (FDA) announced full approval for Leqembiā¢, the brand name for lecanemab (BAN-2401), for the treatment of Alzheimerās disease. The availability of a therapy for early stages of the disease is a tremendous milestone for Alzheimerās patients and caregivers. This breakthrough ...
July 7, 2023
2019 A growing number of Alzheimerās disease genes are linked to innate immunity and neuroinflammatory pathways. AD mouse models have been used to test the effects of these microglial genes on AD pathogenesis. However, it has not been possible to precisely test the impact of AD-associated microglial genetic variant due to ...
December 20, 2018
